Teneobio, Inc. has entered into a research collaboration and licensing agreement with TESARO, Inc. to develop novel multi-specific antibodies for up to six undisclosed oncology targets.  Under the terms of the agreement, Teneobio will generate product candidates using its proprietary UniRat transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. TESARO will have exclusive licenses to the antibodies for clinical deve...